Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Cancer Survivorship
Published in: Journal of Cancer Survivorship 4/2014

01-12-2014

The course of anxiety and depression for patients with Hodgkin’s lymphoma or diffuse large B cell lymphoma: a longitudinal study of the PROFILES registry

Authors: Simone Oerlemans, Floortje Mols, Marten R. Nijziel, Wobbe P. Zijlstra, Jan Willem W. Coebergh, Lonneke V. van de Poll-Franse

Published in: Journal of Cancer Survivorship | Issue 4/2014

Login to get access

Abstract

Purpose

The purpose of this study is to prospectively assess anxiety and depression among patients with Hodgkin lymphoma (HL) and diffuse large B cell lymphoma (DLBCL). Also, to compare its prevalence with a normative population, identify subgroups with more anxiety and depression, and assess its impact on health-related quality of life (HRQoL).

Methods

The population-based Eindhoven Cancer Registry was used to select patients diagnosed with HL or DLBCL from 1999 to 2010, 489 responded (T1). The HADS was completed four times (T1–T4), with a 1-year interval. Linear mixed-models were used to assess the course of anxiety and depression and identify high-risk subgroups.

Results

Both anxiety and depression were reported more often by patients compared to the normative population (p < 0.05). Over the four time points, approximately 10 % of patients reported to be always and 15 % reported to be sometimes anxious or depressed. Anxiety and depression did not improve in time. Patients with comorbidity and patients who were lower educated reported higher anxiety and depression scores (p < 0.05). Younger DLBCL patients reported higher anxiety scores, whereas older DLBCL patients reported higher depression scores over time (p < 0.05). Global health status/HRQoL was clinically relevant lower in patients with anxiety and depression and this appeared to be constant over time.

Conclusion

More HL and DLBCL patients experience anxiety and depression compared to their counterparts in the general population and it did not improve in time.

Implication for Cancer Survivors

Clinicians should be aware that former lymphoma patients with anxiety and depression have a deteriorated global health status/HRQoL and refer patients to suitable aftercare when necessary.
Literature
1.
2.
van de Schans SA, Issa DE, Visser O, et al. Diverging trends in incidence and mortality, and improved survival of non-Hodgkin's lymphoma, in the Netherlands, 1989–2007. Ann Oncol. 2012;23:171–82.CrossRefPubMed
3.
Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol. 2003;21:3431–9.CrossRefPubMed
4.
De Bruin ML, Sparidans J, van't Veer MB, et al. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes. J Clin Oncol. 2009;27:4239–46.CrossRefPubMed
5.
Hess SL, Johannsdottir IM, Hamre H, et al. Adult survivors of childhood malignant lymphoma are not aware of their risk of late effects. Acta Oncol 2011.
6.
Knobel H, Loge J, Brit Lund M, et al. Late medical complications and fatigue in Hodgkin's disease survivors. J Clin Oncol. 2001;19:3226–33.PubMed
7.
Ng AK, LaCasce A, Travis LB. Long-term complications of lymphoma and its treatment. J Clin Oncol. 2011;29:1885–92.CrossRefPubMed
8.
Ruiz-Soto R, Sergent G, Gisselbrecht C, et al. Estimating late adverse events using competing risks after autologous stem-cell transplantation in aggressive non-Hodgkin lymphoma patients. Cancer. 2005;104:2735–42.CrossRefPubMed
9.
Seshadri T, Pintilie M, Kuruvilla J, et al. Incidence and risk factors for second cancers after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Leuk Lymphoma. 2009;50:380–6.CrossRefPubMed
10.
van den Belt-Dusebout AW, Aleman BM, Besseling G, et al. Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy. Int J Radiat Oncol Biol Phys. 2009;75:1420–9.CrossRefPubMed
11.
Bellizzi KM, Rowland JH, Arora NK, et al. Physical activity and quality of life in adult survivors of non-Hodgkin's lymphoma. J Clin Oncol. 2009;27:960–6.PubMedCentralCrossRefPubMed
12.
Doorduijn J, Buijt I, Holt B, et al. Self-reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy. Eur J Haematol. 2005;75:116–23.CrossRefPubMed
13.
Hjermstad MJ, Fossa SD, Oldervoll L, et al. Fatigue in long-term Hodgkin's Disease survivors: a follow-up study. J Clin Oncol. 2005;23:6587–95.CrossRefPubMed
14.
Loge JH, Abrahamsen AF, Ekeberg O, et al. Psychological distress after cancer cure: a survey of 459 Hodgkin's disease survivors. Br J Cancer. 1997;76:791–6.PubMedCentralCrossRefPubMed
15.
Merli F, Bertini M, Luminari S, et al. Quality of life assessment in elderly patients with aggressive non-Hodgkin's lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano Linfomi. Haematologica. 2004;89:973–8.PubMed
16.
Mols F, Aaronson NK, Vingerhoets AJ, et al. Quality of life among long-term non-Hodgkin lymphoma survivors: a population-based study. Cancer. 2007;109:1659–67.CrossRefPubMed
17.
Oerlemans S, Mols F, Issa DE, et al. A high level of fatigue among (long-term) non-Hodgkin lymphoma survivors: results from the longitudinal population-based PROFILES registry in the south of the Netherlands. Haematologica 2012.
18.
Oerlemans S, Mols F, Nijziel MR, et al. The impact of treatment, socio-demographic and clinical characteristics on health-related quality of life among Hodgkin's and non-Hodgkin's lymphoma survivors: a systematic review. Ann Hematol. 2011;90:993–1004.PubMedCentralCrossRefPubMed
19.
Pettengell R, Donatti C, Hoskin P, et al. The impact of follicular lymphoma on health-related quality of life. Ann Oncol. 2008;19:570–6.CrossRefPubMed
20.
Hjermstad MJ, Knobel H, Brinch L, et al. A prospective study of health-related quality of life, fatigue, anxiety and depression 3–5 years after stem cell transplantation. Bone Marrow Transplant. 2004;34:257–66.CrossRefPubMed
21.
Hjermstad MJ, Loge JH, Evensen SA, et al. The course of anxiety and depression during the first year after allogeneic or autologous stem cell transplantation. Bone Marrow Transplant. 1999;24:1219–28.CrossRefPubMed
22.
Wang Y, Zou L, Jiang M, et al. Measurement of distress in Chinese inpatients with lymphoma. Psychooncology 2012.
23.
Thompson CA, Charlson ME, Schenkein E, et al. Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors. Ann Oncol. 2010;21:2262–6.PubMedCentralCrossRefPubMed
24.
Fritz A, Percy C, Jack A, et al. International classification of diseases for oncology. 3rd ed. Geneva: World Health Organisation; 2000.
25.
26.
Snaith RP, Zigmond AS. The hospital anxiety and depression scale. Br Med J (Clin Res Ed). 1986;292:344.CrossRef
27.
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–70.CrossRefPubMed
28.
Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.CrossRefPubMed
29.
Sangha O, Stucki G, Liang MH, et al. The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum. 2003;49:156–63.CrossRefPubMed
30.
Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971;31:1860–1.PubMed
31.
van de Poll-Franse LV, Horevoorts N, Eenbergen MV, et al. The patient reported outcomes following initial treatment and long term evaluation of survivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts. Eur J Cancer 2011.
32.
van de Poll-Franse LV, Mols F, Gundy CM, et al. Normative data for the EORTC QLQ-C30 and EORTC-sexuality items in the general Dutch population. Eur J Cancer 2011.
33.
Hedeker DR, Gibbons RD. Longitudinal data analysis. Chapter 6. Hoboken, New Jersey: Wiley; 2006.
34.
Cohen J, Cohen P, West SG, Aiken LS. Applied multiple regression/correlation analysis for the behavioral sciences. Chapter 7. Mahwah, NJ: Erlbaum; 2003.
35.
Cocks K, King MT, Velikova G, et al. Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol. 2011;29:89–96.CrossRefPubMed
36.
Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41:582–92.PubMed
37.
Norman GR, Sridhar FG, Guyatt GH, Walter SD. Relation of distribution- and anchor-based approaches in interpretation of changes in health-related quality of life. Med Care. 2001;39:1039–47.CrossRefPubMed
38.
van der Poel MWM, Oerlemans S, Schouten HC, et al. Quality of life more impaired in younger than in older diffuse large B-cell lymphoma survivors compared to a normative population: a study from the population-based PROFILES registry Annals of Hematology 2013
39.
Husson O, Mols F, van de Poll-Franse LV. The relation between information provision and health-related quality of life, anxiety and depression among cancer survivors: a systematic review. Ann Oncol. 2011;22:761–72.PubMedCentralCrossRefPubMed
40.
Oerlemans S, Husson O, Mols F, et al. Perceived information provision and satisfaction among lymphoma and multiple myeloma survivors-results from a Dutch population-based study. Ann Hematol 2012.
41.
Mols F, Husson O, Roukema JA, van de Poll-Franse LV. Depressive symptoms are a risk factor for all-cause mortality: results from a prospective population-based study among 3,080 cancer survivors from the PROFILES registry. J Cancer Surviv. 2013;7:484–92.CrossRefPubMed
Metadata
Title
The course of anxiety and depression for patients with Hodgkin’s lymphoma or diffuse large B cell lymphoma: a longitudinal study of the PROFILES registry
Authors
Simone Oerlemans
Floortje Mols
Marten R. Nijziel
Wobbe P. Zijlstra
Jan Willem W. Coebergh
Lonneke V. van de Poll-Franse
Publication date
01-12-2014
Publisher
Springer US
Published in
Journal of Cancer Survivorship / Issue 4/2014
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-014-0367-1

Other articles of this Issue 4/2014

Journal of Cancer Survivorship 4/2014 Go to the issue

OriginalPaper

Associations among survivorship care plans, experiences of survivorship care, and functioning in older breast cancer survivors: CALGB/Alliance 369901

OriginalPaper

Childhood cancer survivors and adherence to the American Cancer Society Guidelines on Nutrition and Physical Activity

OriginalPaper

Neurologic morbidity and quality of life in survivors of childhood acute lymphoblastic leukemia: a prospective cross-sectional study

OriginalPaper

Pre- to post-diagnosis weight change and associations with physical functional limitations in breast cancer survivors

OriginalPaper

Endocrine therapy initiation among Medicaid-insured breast cancer survivors with hormone receptor-positive tumors

Review

Fertility and parenthood issues in young female cancer patients—a systematic review
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits